Characterization of tumour mutation burden in patients with non‐small cell lung cancer and interstitial lung disease

BACKGROUND AND OBJECTIVE: The efficacy expectation of immune checkpoint inhibitors against NSCLC in patients with ILD seems to be high because these populations are supposed to have high TMB. However, information about the characterization of TMB in patients with NSCLC and ILD is limited. Therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Haruki, Serizawa, Masakuni, Naito, Tateaki, Konno, Hayato, Kojima, Hideaki, Mizuno, Tetsuya, Isaka, Mitsuhiro, Endo, Masahiro, Nagashima, Takeshi, Kusuhara, Masatoshi, Urakami, Kenichi, Ohshima, Keiichi, Yamaguchi, Ken, Ohde, Yasuhisa, Takahashi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496253/
https://www.ncbi.nlm.nih.gov/pubmed/31694070
http://dx.doi.org/10.1111/resp.13726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496253/
https://www.ncbi.nlm.nih.gov/pubmed/31694070
http://dx.doi.org/10.1111/resp.13726

Ejemplares similares